Jing L. Marantz, Executive Vice President and Chief Medical Officer of Intellia Therapeutics, Inc., filed an initial statement of beneficial ownership on October 28, 2026, with a triggering event date of October 26, 2026.

Key Highlights

  • Reporting person: Jing L. Marantz, identified in the filing as EVP, Chief Medical Officer of Intellia Therapeutics, Inc.
  • Event date: The date of the event requiring the statement is listed as October 26, 2026.
  • No securities held: The filing states "No securities are beneficially owned" in both Table I (non-derivative securities) and Table II (derivative securities).
  • Filing date: The form was signed and filed on October 28, 2026, by James Basta as attorney-in-fact.
  • Issuer: Intellia Therapeutics, Inc., trading on NASDAQ:NTLA, headquartered at 400 Technology Square, Suite 100, Cambridge, Massachusetts 02139.

Marantz Reports Zero Initial Holdings Upon Joining Intellia Therapeutics

According to the filing, Jing L. Marantz submitted a Form 3 - Initial Statement of Beneficial Ownership of Securities - in connection with becoming an officer of Intellia Therapeutics, Inc. (NASDAQ:NTLA). The triggering event that required the filing occurred on October 26, 2026, two days before the form was submitted to the SEC.

The filing identifies Marantz's relationship to the issuer as an officer, with the specific title listed as "EVP, Chief Medical Officer." The form was filed by one reporting person and was signed by James Basta acting as attorney-in-fact under a Power of Attorney, which is referenced as Exhibit 24.1 in the filing's remarks section.

Both Table I, covering non-derivative securities, and Table II, covering derivative securities such as puts, calls, warrants, options, and convertible securities, are left blank. The filing explicitly states "No securities are beneficially owned," indicating that Marantz held no direct or indirect beneficial ownership of Intellia Therapeutics securities at the time of the triggering event.

What Was Disclosed

Jing L. Marantz, EVP and Chief Medical Officer of Intellia Therapeutics, filed an initial beneficial ownership statement reporting zero securities held, either directly or indirectly, in any security class of the issuer as of October 26, 2026.